The instruction for medical use
of TOKSIVENOL medicine
the Trade name
Toksivenol
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for injections of 3 ml 150 mg / 1.5 mg
Structure
1 ampoule of drug (3 ml) contains
active agents: trokserutin 150 mg
carboazochrome of 1.5 mg,
excipients: sodium chloride, water for injections
the Description
Transparent, orange color solution without visible particles
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries.
Bioflavonoids.
The code of automatic telephone exchange C05CA54
the Pharmacological
Pharmacokinetics Maximum Concentration properties in blood plasma are reached between the 2nd and 8th hours. The second maximum of plasma concentration is shown about the thirtieth hour after administration of drug. Linking with plasma proteins makes about 30%. It is metabolized in a liver to aglyukogonny forms mono - di – and trigidroksietilrutozid, glucuronides
and derivatives of arylacetic acid. Elimination half-life varies of 10 - 25 o'clock. About 25%, with bile – about 70% are allocated with urine.
Concentration of carboazochrome in blood plasma is found in 10 min. after use, average peak concentration in blood plasma (Cmax) makes 21.0 ±8.4 ng/ml, and time of achievement of peak of Tmax is 1.2±0.5 h. Elimination half-life of T1/2 - 2.5 ± 0.9 h. The Average Time of Keeping (ATK) and the area under a curve of dependence of concentration from time from 2 h to 8 h makes 4.1 ± 1.1 h and 65.9 ±25.3 h ng/m, respectively.
The pharmacodynamics
Toksivenol - an optimum combination of the making components of a trokserutin and carboazochrome causes high pharmacological efficiency of drug that will allow to carry out purposefully treatment of vascular diseases and syndromes of bleeding at the increased weakness of walls of capillaries.
Trokserutin possesses P – vitamin activity, shows the significant angioprotektivny properties, restores the broken permeability of capillary vessels, reduces fragility of capillaries, provides their elasticity, an upryagost and resistance to traumatic damages.
The pharmacological effect of drug causes strengthening of effect of the vitamin C performing protective function of permeability of a membrane and activates production of hyaluronic acid – mucopolysaccharide, the walls of vessels which are responsible for density. Besides, decrease in release of a histamine, substance vasodilating and causing hypostasis is observed.
Karbazokhr – orthoquinone, a product of oxidation of adrenaline without sympathomimetic activity because of an otsustviye of minor amine group and group about – biphenol. Vasoconstrictive local action on small vessels of the bleeding zone influences reduction of duration of bleeding. This phenomenon occurs without increase in arterial blood pressure and influence on warm activity. It is revealed that carboazochrome explicitly influences durability and permeability of capillaries and also a tone and the reducing force of vessels.
Indications
- chronic venous insufficiency, a varicosity, superficial thrombophlebitis, a periphlebitis, posttraumatic hypostasis, hematomas, trophic disturbance at chronic venous insufficiency (dermatitis, trophic ulcers)
- the hemorrhoidal
Route of administration nodes and doses
the Mode of dosing and duration of a course of treatment is defined by the attending physician.
For intramuscular injections use 3 – 9 ml a day.
Course of treatment of 14 days.
For maintenance therapy use drug in tablets.
Side effects
- allergic reactions
- painful feelings in the injection site of drug
- nausea
- face reddening
- a headache
- swelling and an abdominal pain
of the Contraindication
- hypersensitivity to drug components
- children's and teenage age up to 18 years
- pregnancy and the period of a lactation
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Contents of ampoules cannot be mixed with the solutions containing ascorbic acid.
Special indications
of Feature of influence of medicine on ability to run the vehicle or potentially dangerous mekhanizmamiuchityvy side effects of medicine it is necessary to be careful when driving or potentially dangerous mechanisms.
Overdose
Symptoms - strengthening of side effects of drug.
Treatment is symptomatic.
A form of release and packing
On 3 ml of drug in ampoules from amber glass. On ampoules the text of marking is applied with the fast-fixed paint.
On 5 ampoules place in a plastic pallet.
On 2 pallets together with the instruction for medical use in the state and Russian languages place
Storage conditions in a cardboard pack
to Store in the dry place at a temperature not above 25ºС.
To store out of children's reach!
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the ROTAFARM company, Great Britain
KLEVA S.A Is made., Parnitos 189 Ave., 13671 Athens, Greece
According to the license AKARPIA of Servikos Pharmatseutikos of LDA, Portugal.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya St., 222b
Ph. / fax: 2718066, 2717692
www.worldmedicine.kz
of TOKSIVENOL medicine
the Trade name
Toksivenol
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Solution for injections of 3 ml 150 mg / 1.5 mg
Structure
1 ampoule of drug (3 ml) contains
active agents: trokserutin 150 mg
carboazochrome of 1.5 mg,
excipients: sodium chloride, water for injections
the Description
Transparent, orange color solution without visible particles
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries.
Bioflavonoids.
The code of automatic telephone exchange C05CA54
the Pharmacological
Pharmacokinetics Maximum Concentration properties in blood plasma are reached between the 2nd and 8th hours. The second maximum of plasma concentration is shown about the thirtieth hour after administration of drug. Linking with plasma proteins makes about 30%. It is metabolized in a liver to aglyukogonny forms mono - di – and trigidroksietilrutozid, glucuronides
and derivatives of arylacetic acid. Elimination half-life varies of 10 - 25 o'clock. About 25%, with bile – about 70% are allocated with urine.
Concentration of carboazochrome in blood plasma is found in 10 min. after use, average peak concentration in blood plasma (Cmax) makes 21.0 ±8.4 ng/ml, and time of achievement of peak of Tmax is 1.2±0.5 h. Elimination half-life of T1/2 - 2.5 ± 0.9 h. The Average Time of Keeping (ATK) and the area under a curve of dependence of concentration from time from 2 h to 8 h makes 4.1 ± 1.1 h and 65.9 ±25.3 h ng/m, respectively.
The pharmacodynamics
Toksivenol - an optimum combination of the making components of a trokserutin and carboazochrome causes high pharmacological efficiency of drug that will allow to carry out purposefully treatment of vascular diseases and syndromes of bleeding at the increased weakness of walls of capillaries.
Trokserutin possesses P – vitamin activity, shows the significant angioprotektivny properties, restores the broken permeability of capillary vessels, reduces fragility of capillaries, provides their elasticity, an upryagost and resistance to traumatic damages.
The pharmacological effect of drug causes strengthening of effect of the vitamin C performing protective function of permeability of a membrane and activates production of hyaluronic acid – mucopolysaccharide, the walls of vessels which are responsible for density. Besides, decrease in release of a histamine, substance vasodilating and causing hypostasis is observed.
Karbazokhr – orthoquinone, a product of oxidation of adrenaline without sympathomimetic activity because of an otsustviye of minor amine group and group about – biphenol. Vasoconstrictive local action on small vessels of the bleeding zone influences reduction of duration of bleeding. This phenomenon occurs without increase in arterial blood pressure and influence on warm activity. It is revealed that carboazochrome explicitly influences durability and permeability of capillaries and also a tone and the reducing force of vessels.
Indications
- chronic venous insufficiency, a varicosity, superficial thrombophlebitis, a periphlebitis, posttraumatic hypostasis, hematomas, trophic disturbance at chronic venous insufficiency (dermatitis, trophic ulcers)
- the hemorrhoidal
Route of administration nodes and doses
the Mode of dosing and duration of a course of treatment is defined by the attending physician.
For intramuscular injections use 3 – 9 ml a day.
Course of treatment of 14 days.
For maintenance therapy use drug in tablets.
Side effects
- allergic reactions
- painful feelings in the injection site of drug
- nausea
- face reddening
- a headache
- swelling and an abdominal pain
of the Contraindication
- hypersensitivity to drug components
- children's and teenage age up to 18 years
- pregnancy and the period of a lactation
Medicinal interactions
Strengthens effect of ascorbic acid on structure and permeability of a vascular wall.
Contents of ampoules cannot be mixed with the solutions containing ascorbic acid.
Special indications
of Feature of influence of medicine on ability to run the vehicle or potentially dangerous mekhanizmamiuchityvy side effects of medicine it is necessary to be careful when driving or potentially dangerous mechanisms.
Overdose
Symptoms - strengthening of side effects of drug.
Treatment is symptomatic.
A form of release and packing
On 3 ml of drug in ampoules from amber glass. On ampoules the text of marking is applied with the fast-fixed paint.
On 5 ampoules place in a plastic pallet.
On 2 pallets together with the instruction for medical use in the state and Russian languages place
Storage conditions in a cardboard pack
to Store in the dry place at a temperature not above 25ºС.
To store out of children's reach!
Not to apply a period of storage of 5 years after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the ROTAFARM company, Great Britain
KLEVA S.A Is made., Parnitos 189 Ave., 13671 Athens, Greece
According to the license AKARPIA of Servikos Pharmatseutikos of LDA, Portugal.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya St., 222b
Ph. / fax: 2718066, 2717692
www.worldmedicine.kz
Related Products
Borshchahivskiy CPP/BCPP (Ukraine)
Corvitin 0.5g 5's lyophilized powder for solution for injection
$165.80
